"We have developed a nano-technology, which first delivers an anticancer drug specifically to the tumour, and if the tumour starts dying or regressing, it then starts lighting up the tumour in real time," said Shiladitya Sen Gupta, a principal investigator at Massachusetts Institute of Technology's (MIT) Brigham and Women's Hospital (BWH).
"This way you can monitor whether a chemotherapy is working or not in real time, and switch the patients to the right drug early on. One doesn't need to wait for months while taking a toxic chemotherapy only to realise later and after side effects that the drug hasn't worked," Gupta, a co-corresponding author of the breakthrough research published online this week in 'The Proceedings of the National Academy of Sciences', told PTI.
Kulkarni said by using this approach, the cells light up the moment a cancer drug starts working.
"We can determine if a cancer therapy is effective within hours of treatment. Our long-term goal is to find a way to monitor outcomes very early so that we don't give a chemotherapy drug to patients who are not responding to it," he said.
Other members of the research team are Poornima Rao, Siva Natarajana, Aaron Goldman, Venkata S Sabbisetti, Yashika Khater, Navya Korimerla, Vineethkrishna Chandrasekara and Raghunath A Mashelkar.
Except Goldman, all are Indian researchers.
"Current techniques, which rely on measurements of the size or metabolic state of the tumour, are sometimes unable to detect the effectiveness of an immunotherapeutic agent as the volume of the tumour may actually increase as immune cells begin to flood in to attack the tumour," Kulkarni said.
The technology developed by the group can be used for monitoring the effectiveness of immunotherapy, a report said.
Using a nanoparticle that delivers a drug and then fluoresces green when cancer cells begin dying, they were able to visualise whether a tumour is resistant or susceptible to a particular treatment much sooner than currently available clinical methods, said a statement from BWH.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
